188 related articles for article (PubMed ID: 10825126)
1. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
Scheffer GL; Maliepaard M; Pijnenborg AC; van Gastelen MA; de Jong MC; Schroeijers AB; van der Kolk DM; Allen JD; Ross DD; van der Valk P; Dalton WS; Schellens JH; Scheper RJ
Cancer Res; 2000 May; 60(10):2589-93. PubMed ID: 10825126
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric analysis of breast cancer resistance protein expression and function.
Minderman H; Suvannasankha A; O'Loughlin KL; Scheffer GL; Scheper RJ; Robey RW; Baer MR
Cytometry; 2002 Jun; 48(2):59-65. PubMed ID: 12116365
[TBL] [Abstract][Full Text] [Related]
3. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
4. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Schellens JH; Maliepaard M; Scheper RJ; Scheffer GL; Jonker JW; Smit JW; Beijnen JH; Schinkel AH
Ann N Y Acad Sci; 2000; 922():188-94. PubMed ID: 11193894
[TBL] [Abstract][Full Text] [Related]
5. [Drug-resistant proteins in breast cancer: recent progress in multidrug resistance].
Wu DL; Huang F; Lu HZ
Ai Zheng; 2003 Apr; 22(4):441-4. PubMed ID: 12704006
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
7. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
Maliepaard M; Scheffer GL; Faneyte IF; van Gastelen MA; Pijnenborg AC; Schinkel AH; van De Vijver MJ; Scheper RJ; Schellens JH
Cancer Res; 2001 Apr; 61(8):3458-64. PubMed ID: 11309308
[TBL] [Abstract][Full Text] [Related]
8. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
Shepard RL; Cao J; Starling JJ; Dantzig AH
Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
[TBL] [Abstract][Full Text] [Related]
9. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Maliepaard M; van Gastelen MA; de Jong LA; Pluim D; van Waardenburg RC; Ruevekamp-Helmers MC; Floot BG; Schellens JH
Cancer Res; 1999 Sep; 59(18):4559-63. PubMed ID: 10493507
[TBL] [Abstract][Full Text] [Related]
12. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
13. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
14. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
16. Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.
Kowalski P; Wichert A; Holm PS; Dietel M; Lage H
Cancer Gene Ther; 2001 Mar; 8(3):185-92. PubMed ID: 11332989
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
18. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Ross DD; Yang W; Abruzzo LV; Dalton WS; Schneider E; Lage H; Dietel M; Greenberger L; Cole SP; Doyle LA
J Natl Cancer Inst; 1999 Mar; 91(5):429-33. PubMed ID: 10070941
[TBL] [Abstract][Full Text] [Related]
19. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
20. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]